Our website uses cookies to bring you an easy and personalised browsing experience. By continuing, you consent to our cookie policy on this device. For More info, please see our Privacy Statement

ICECaP

Engaging a community of investigators and patient representatives to create and develop a global strategic approach to decrease deaths from prostate cancer

Objectives and Aims

01

Greater integration of all scientific disciplines, pharma companies, co-operative groups, regulatory agencies and patient representatives for designing and conducting and analyzing clinical trial and registry data. This will limit needless duplication while preserving and harnessing opportunities for assessing requisite reproducibility of findings.

02

Integration of new endpoints into clinical trials that expedite the determination of whether new therapies improve the outcome (survival and quality of life) of men with high risk, localized and metastatic hormone-sensitive prostate cancer.

03

Validation of putative biomarkers (tissue or blood-based, imaging) to help assign the right therapy for the right patient at the right time.

ICECaP collaboration honored for statistical excellence in accelerating therapeutic advances for Prostate Cancer.

The ICECaP collaboration has received the 2021 Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award, recognizing the integral role of statisticians to improve the care of men diagnosed with prostate cancer.  Full Press Release here.

Read about this Award in the American Statistical Association Membership Magazine, or Online.

Input your text in this area

Funding Acknowledgement

The ICECaP collaboration was made possible by the lead investment from the Prostate Cancer Foundation (PCF) in 2013 as part of their Challenge Award grant mechanisms.

Christopher Sweeney, ICECaP Principal Investigator
Presenting plans at Prostate Cancer Foundation Scientific Retreat. Further funding has been achieved as part of an academic-pharma partnership.

ICECaP1

2013-2017 Funding period

  • Prostate Cancer Foundation Challenge Award
  • Millennium Pharmaceuticals (via PCF)
  • Janssen (via PCF)
  • Sanofi (via PCF)
  • Astellas / Medivation
  • Sotio (via PCF)

ICECaP2

2018-Ongoing Funding period

  • Janssen (via PCF)
  • Dendreon (Via PCF)
  • Sanofi (via PCF)
  • Astellas / Pfizer
  • Bayer

ICECaP Biology

Funding / In-kind support

  • DECIPHER Biosciences
  • U.S. Department of Defense
  • National Cancer Institute
  • Prostate Cancer UK
  • Prostate Cancer Foundation
  • John Black Charitable Foundation
  • Prostate Cancer Research
  • Benioff Initiative for Prostate Cancer Research

STOPCAP M1


  • Prostate Cancer UK Innovations award
    (for efficacy reviews)
  • PCF Challenge Award
    (for surrogacy/prognosis analyses)

Health Economics

ANZUP in collaboration with the Centre for Health Economics Research and Evaluation (University of Technology Sydney), with funding support from:

  • Astellas Australia
  • Janssen Australia

Movember - ICECaP Collaboration.

Movember is partnering with the ICECaP Consortium to leverage the natural alignment of our shared goal to accelerate global progress on developing a strategic approach to significantly reduce the number of men dying from prostate cancer.

The in-kind support from the Movember team for overall logistics and communication will provide the requisite platforms for dissemination to and engagement with all stakeholders.

Read about Projects